Articles related to VISION LOSS

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

Primary trabeculectomy reduced the rate of visual field loss by approximately 50% compared with a medications-first approach in newly diagnosed advanced open-angle glaucoma patients across a 5-year randomized trial, though standard quality-of-life instruments failed to detect that clinical benefit.

Erucamide, a naturally occurring lipid molecule, declined as photoreceptors deteriorated in preclinical retinal degeneration models, and restoring it via nanoparticle delivery slowed aspects of tissue breakdown without reversing damage.

The American Academy of Ophthalmology updated hydroxychloroquine retinopathy screening recommendations, emphasizing dose limits, OCT and FAF as primary screening modalities, and risk stratification by renal status and concurrent tamoxifen use.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

Vigabatrin can cause irreversible peripheral retinal toxicity that is often asymptomatic, underscoring the need for consistent ophthalmic monitoring in treated patients.